INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 414m ago
HOUSE PTR13m ago
SEC 13F13m ago
ROBINHOOD CHAIN13m ago
SEC FORM 4/Grant or awardVerified data

Martin Samuel Bates reported CLDX

SVP AND CFO · Celldex Therapeutics, Inc. · Celldex Therapeutics, Inc. — Incentive Stock Option (right to buy)

Side
A
Value
—
Shares
93.0K
Price
—
Executed
Jun 25, 2026
Disclosed
Jun 29, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Jun 25 executedJun 29, 2026 disclosed

CLDX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · CLDX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    CE
    Crowley ElizabethSR. VP & CPDO
    CLDXCelldex Therapeutics, Inc.
    Grant or award
    		A—
    100.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    9
    HM
    Heath-Chiozzi MargoSVP OF REGULATORY AFFAIRS
    CLDXCelldex Therapeutics, Inc.
    Grant or award
    		A—
    95.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    9
    CS
    Cavanaugh SarahSVP OF CORP AFFAIRS & ADMIN.
    CLDXCelldex Therapeutics, Inc.
    Grant or award
    		A—
    95.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    9
    JR
    Jain RitaDirector
    CLDXCelldex Therapeutics, Inc.
    Grant or award
    		A—
    26.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    9
    LL
    Lawver Teri LSVP & Chief Commercial Officer
    CLDXCelldex Therapeutics, Inc.
    Grant or award
    		A—
    90.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    5
    JA
    Jimenez Freddy A.SVP & GENERAL COUNSEL
    CLDXCelldex Therapeutics, Inc.
    Grant or award
    		A—
    93.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    9
    TD
    Torres DeniceDirector
    CLDXCelldex Therapeutics, Inc.
    Grant or award
    		A—
    26.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    28
    JA
    Jimenez Freddy A.SVP & GENERAL COUNSEL
    CLDXCelldex Therapeutics, Inc.
    Open-market sale
    		SELL$121K
    4,166 sh
    		Dec 4, 2025Dec 8, 2025
    traded Dec 4, 2025
    		+4dSEC FORM 4

    Evidence

    9
    LL
    Lawver Teri LSVP & Chief Commercial Officer
    CLDXCelldex Therapeutics, Inc.
    Grant or award
    		A—
    100.0K sh
    		Nov 10, 2025Nov 12, 2025
    traded Nov 10, 2025
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001709024-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jun 25, 2026
    Published
    Jun 29, 2026
    Ingested by INSIDER
    Nov 5, 03:50 UTC
    Last re-read
    Nov 5, 03:50 UTC

    Extracted facts

    Filer
    Martin Samuel Bates
    Role
    SVP AND CFO
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Celldex Therapeutics, Inc. — Incentive Stock Option (right to buy)
    Ticker
    CLDX
    Shares
    93.0K
    Price per share
    $0
    Execution date (reported)
    Jun 25, 2026
    Owned after transaction
    93.0K shares
    Days from execution to publication
    4

    What this establishes

    Martin Samuel Bates filed this Form 4 reporting a grant or award of CLDX on Jun 25, 2026. It became public on Jun 29, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    SVP AND CFO
    Martin Samuel Batescik:0001709024
    Issuer
    Celldex Therapeutics, Inc.cik:0000744218

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.